FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease

The new drug is for patients with von Hippel-Lindau disease who require therapy for a number of associated cancers, including renal cell carcinoma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news